Jared Berberabe[email protected]Trends and FinanceLong COVID outpaces diabetes in 2022 employer health spendingThe firm said that it conducted an extensive study to examine the costs of long COVID and its associated conditions -- breathing abnormalities, malaise and fatigue, cough, throat and chest pain, and respiratory failure.August 30, 2022Breast CancercfDNA detection may simplify breast cancer monitoring: studyIn a study published recently in Science Advances, the researchers found that plasma cell-free DNA (cfDNA) contains high resolution, genome-wide binding estrogen receptors (ER) and FOXA1 profiles for breast cancer.August 30, 2022Previous PagePage 3 of 3Top StoriesFDA ClearancePillar Biosciences gets FDA approval for NGS solid tumor profiling testPillar Biosciences has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its OncoReveal CDx pan-cancer next-generation sequencing (NGS) test for general solid tumor profiling.ValidationImmunovia announces positive results for next-gen pancreatic cancer testCollaborationVertex to pay $25M upfront to scale cell manufacturing technologyMergers & AcquisitionsLabcorp buys Invitae portfolio for $239MSponsor ContentVisit our Molecular Diagnostics Community